Authors

• Gilles Defer (ORCID: https://orcid.org/0000-0003-1343-5858)
• Gavin Giovannoni (ORCID: https://orcid.org/0000-0001-9995-1700)
• John Foley (ORCID: https://orcid.org/0000-0003-0431-7067)
• Helmut Butzkueven (ORCID: https://orcid.org/0000-0003-3940-8727)
• Tyler Lasky
• Gary Cutter (ORCID: https://orcid.org/0000-0002-8455-980X)
• Kyle Ferber (ORCID: https://orcid.org/0000-0002-4730-6993)
• Heinz Wiendl (ORCID: https://orcid.org/0000-0003-4310-3432)
• Jeffrey Allen Cohen (ORCID: https://orcid.org/0000-0001-9245-9772)
• Douglas Lorne Arnold (ORCID: https://orcid.org/0000-0003-4266-0106)
• Lana Zhovtis Ryerson (ORCID: https://orcid.org/0000-0003-1868-3893)
• Joep Killestein (ORCID: https://orcid.org/0000-0002-6347-5957)
• Kexuan Li (ORCID: https://orcid.org/0009-0006-0765-0032)
• Marie Toukam
• Holly Engelman
• Liesel D’silva
• J.-H. Sohn

Institutions

• Montreal Neurological Institute and Hospital (CA)

Publication Details

Journal

Neurology Neuroimmunology & Neuroinflammation

Published

2024-10-11

DOI

https://doi.org/10.1212/nxi.0000000000200321

Citations

5

Primary Topic

Multiple Sclerosis Research Studies

Type

article

Field-Weighted Citation Impact

2.12

Funders

• Bristol-Myers Squibb
• Eli Lilly and Company
• Sanofi
• Biogen
• Teva Pharmaceutical Industries
• Alexion Pharmaceuticals
• Celgene
• Shionogi
• Genentech
• EMD Serono
• Sanofi Genzyme
• UCB Pharma